Clinical Trials Browser

Has results × Recurrence × Bortezomib × Clear all

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 2 FDA

Multiple Myeloma, Recurrence

NCT02654990 2024-07-12

PANORAMA_3

Phase 2 Completed

248 enrolled 28 charts

Multiple Myeloma, Recurrence

NCT00464178 2022-07-20

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

7 enrolled 5 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00256776 2021-10-18

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

Phase 3 Terminated

269 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT00773838 2021-04-01

MK-0683-095

Phase 2 Completed

143 enrolled 16 charts

Multiple Myeloma, Recurrence

NCT00381940 2021-03-24

Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

Phase 2 Completed

26 enrolled 14 charts

Hodgkin Disease, Recurrence

NCT01023308 2020-03-17

PANORAMA-1

Phase 3 Completed

767 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01504477 2020-03-16

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

Phase 1/2 Terminated

6 enrolled 8 charts

Gastrointestinal

Recurrence, Colorectal Neoplasms

NCT02290431 2019-11-18

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Completed

31 enrolled 19 charts

Multiple Myeloma, Recurrence

NCT02535806 2019-08-13

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Phase 2 Terminated

2 enrolled 11 charts

LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01672736 2018-09-13

A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma

Phase 1/2 Terminated

19 enrolled 10 charts

Multiple Myeloma, Recurrence

NCT00201877 2018-03-12

Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

Phase 2 Completed

25 enrolled 9 charts

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Mantle-Cell

NCT01083602 2017-12-21

MACS1271

Phase 2 Completed

55 enrolled 11 charts

Multiple Myeloma, Recurrence

NCT00547534 2015-08-06

BVR

Phase 2 Completed

31 enrolled 9 charts

Lymphoma, Non-Hodgkin, Recurrence

NCT00536575 2013-02-27

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

Phase 1/2 Completed

13 enrolled 5 charts

Multiple Myeloma, Recurrence